Block Listing Six Monthly Return

RNS Number : 5398U
Oncimmune Holdings PLC
06 April 2021
 

6 April 2021

 

 

Oncimmune Holdings plc

 

("Oncimmune" or the "Company")

 

Block Listing Six Monthly Return

 

 

Oncimmune makes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block admission arrangements in respect of Oncimmune Holdings Plc 2016 Unapproved and EMI Share Option Plans (the "Share Option Plans").

 

Name of applicant:

Oncimmune Holdings plc

 

Name of scheme:

Oncimmune Holdings Plc 2016 Unapproved and EMI Share Option Plans

 

Period of return:

15 September 2020 to 15 March 2021

 

Balance of unallotted securities under scheme(s) from previous return:

 

 5,998,772

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

 

0

Less: Number of securities issued/allotted under scheme(s) during period:

 

 168,618

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

 

 5,830,154

 

 

For further information:

 

Oncimmune Holdings plc

Ron Kirschner, Company Secretary

contact@oncimmune.co.uk

 

Zeus Capital Limited (Nominated Adviser and Joint Broker)

Andrew Jones, Daniel Harris, Victoria Ayton

+44 (0)20 3829 5000

 

N+1 Singer (Joint Broker)

Aubrey Powell, Harry Gooden, Iqra Amin, James Fischer

+44 (0)20 7496 3000

 

WG Partners (Joint Broker)

David Wilson, Chris Lee

+44 (0)203 705 9321

 

Media enquiries:

FTI Consulting

Ben Atwell, Michael Trace, Alex Davis

Oncimmune@fticonsulting.com

+44 (0)20 3727 1000

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BLRSSWFEMEFSELL
UK 100

Latest directors dealings